Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp Issues Q4 2013 Guidance; Narrows FY 2013 Revenue Guidance To A Range In Line With Estimates; Raises Low End of Prior FY 2013 EPS Guidance


Thursday, 24 Oct 2013 07:01am EDT 

Boston Scientific Corp announced that fourth quarter of 2013, it expects sales in a range of $1.780 billion to $1.830 billion, earnings on a GAAP basis in a range of $0.04 to $0.08 per share. and Adjusted earnings, excluding acquisition and restructuring related charges and amortization expense, are estimated in a range of $0.18 to $0.20 per share. For fiscal 2013, it expects sales in a range of $7.085 to $7.135 billion and losses on a GAAP basis in a range of ($0.13) to ($0.09) per share. Adjusted earnings, excluding goodwill and intangible asset impairment charges, acquisition-, restructuring-, and litigation-related charges, divestiture-related net credits, debt extinguishment expense and amortization expense; are estimated in a range of $0.69 to $0.71 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $1.828 billion for fourth quarter of 2013; revenue of $7.135 billion for fiscal 2013. 

Company Quote

12.71
0.39 +3.17%
4:00pm EDT